Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook

Back to Search
Print
Bookmark Trial

NCT03722706

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atopic Dermatitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-16
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of atopic dermatitis

- Scheduled for clinic visit for evaluation/management of atopic dermatitis at Boston Children's Hospital

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Parent is Spanish speaking


- Parent is foster parent

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Atopic DermatitisStudy to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
NCT04668066
  1. Anaheim, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Atopic DermatitisAbrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
NCT04564755
  1. Birmingham, Alabama
  2. Lancaster, California
  3. Long Beach, California
  4. San Diego, California
  5. Farmington, Connecticut
  6. Delray Beach, Florida
  7. Hollywood, Florida
  8. Miami, Florida
  9. Sarasota, Florida
  10. Sunrise, Florida
  11. West Dundee, Illinois
  12. Evansville, Indiana
  13. Evansville, Indiana
  14. Lexington, Kentucky
  15. Ypsilanti, Michigan
  16. Bexley, Ohio
  17. Norman, Oklahoma
  18. Rapid City, South Dakota
  19. Memphis, Tennessee
  20. Houston, Texas
  21. Morgantown, West Virginia
  22. Calgary, Alberta
  23. Markham, Ontario
  24. Peterborough, Ontario
  25. Quebec,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Atopic DermatitisWearable Skin Sensors to Assess Nocturnal Scratch Behavior
NCT03770858
  1. Chicago, Illinois
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Atopic DermatitisImprovement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
NCT04008784
  1. Charleston, South Carolina
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook
Official Title  ICMJE Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook
Brief Summary The objective of this research is to evaluate the effectiveness of an educational handbook for parents of children with atopic dermatitis (AD) in improving clinical outcomes for pediatric patients with AD and their parents. The handbook was developed by an interdisciplinary team of healthcare providers to facilitate therapeutic patient education as a routine component of care for pediatric patients with atopic dermatitis (AD). Patient education is an important element of practice management guidelines for AD, particularly given complex treatment plans and high rates of non-adherence in this population. Parents of children with AD will be randomized into either the handbook arm (handbook provided as an adjunct to standard AD management with a healthcare provider at Boston Children's Hospital) or the control arm (standard management alone). Participants will complete study measures at two time points: baseline (prior to a clinic visit appointment for AD care at Boston Children's Hospital), and 3-month follow-up. Data will be analyzed for change on study outcome measures (AD symptoms, AD severity, quality of life) and satisfaction with the handbook.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Dermatitis, Atopic
Intervention  ICMJE Other: Educational handbook
The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
Study Arms  ICMJE
  • Experimental: Handbook
    handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
    Intervention: Other: Educational handbook
  • No Intervention: Control
    standard management alone
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 29, 2020)		246
Original Estimated Enrollment  ICMJE
 (submitted: October 25, 2018)		240
Actual Study Completion Date  ICMJE March 30, 2020
Actual Primary Completion Date March 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of atopic dermatitis
  • Scheduled for clinic visit for evaluation/management of atopic dermatitis at Boston Children's Hospital

Exclusion Criteria:

  • Parent is Spanish speaking
  • Parent is foster parent
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE up to 16 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03722706
Other Study ID Numbers  ICMJE IRB-P00029317
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Jennifer LeBovidge, Boston Children's Hospital
Study Sponsor  ICMJE Boston Children's Hospital
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Jennifer S LeBovidge, PhDBoston Children's Hospital
PRS Account Boston Children's Hospital
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP